Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease

NACompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

January 4, 2016

Primary Completion Date

May 6, 2022

Study Completion Date

June 15, 2022

Conditions
Peripheral Artery Disease
Interventions
BEHAVIORAL

Supervised Treadmill Exercise Therapy

Participants randomized to the exercise intervention will receive supervised treadmill exercise three times weekly for six months.

DRUG

Telmisartan

Participants randomized to the telmisartan arm of the study will take 20 mg or 40 mg of telmisartan daily based on the results of their study run-in. Participants will have their dose increased to up to 80 mg as tolerated.

OTHER

"No exercise control group"

Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months.

DRUG

Placebo

Trial Locations (3)

60611

Northwestern University, Chicago

70112

Tulane University, New Orleans

70121

Ochsner Medical Center, New Orleans

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Northwestern University

OTHER

NCT02593110 - Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease | Biotech Hunter | Biotech Hunter